GenVec

Executive Summary

Licenses radiation-controlled in vivo gene therapy technology from the University of Chicago and Dana Farber Cancer Institute, company announces Nov. 29. The therapeutic genetic therapy, which could be delivered to specific organs via traditional pharmaceutical formulations, can be switched on by radiation at the time and level desired to produce toxins that kill cancer cells. The primary inventors of the technology, Ralph Weichselbaum, MD, University of Chicago, and Dana Farber's Donald Kufe, MD, will become Founding Scientific Advisors of GenVec.